News

Details

Published: 23 September 2019

• portfolio-news

Confo Therapeutics today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Confo Therapeutics is building a portfolio of new medicines based on its proprietary Confo® technology. The technology makes use of antibody fragments or “ConfoBodiesTM” to stabilize G-protein coupled receptors (GPCRs) in their functional conformation, providing a superior starting point for drug design.

Details

Published: 18 September 2019

• portfolio-news

Themis announced today the closing of a Series D financing round totaling EUR 40 million (USD 44 million). The proceeds from this Series D round will be used to accelerate the company’s pivotal Phase 3 clinical trial program for its Chikungunya vaccine and to support further expansion into oncology indications using its proprietary measles vaccine vector platform. Concurrent with the financing, Dr. Walter Stockinger, Managing Partner at Hadean Ventures, will join Themis’ Supervisory Board. 

Details

Published: 29 August 2019

• portfolio-news

Adrenomed announced today that its Supervisory Board has appointed two new members of the Executive Board. Dr. Jens Schneider-Mergener is CEO effective August 1, 2019 and Dr. Jens Zimmerman (CMO) joined the Executive Board effective July 1, 2019. Dr. Schneider-Mergener will succeed Dr. Gerald Möller, who is designated to join Adrenomed’s Supervisory Board. Dr. Schneider-Mergener brings more than 25 years of experience in the biotechnology industry, with a proven track record of successfully transforming a research-stage biotech business into a fully-integrated pharmaceutical company.